Trials / Completed
CompletedNCT00267020
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
A Randomized, Open-Label Phase 2 Study of 2 Regimens, Gemcitabine Plus Enzastaurin and Single-Agent Gemcitabine, in Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | enzastaurin | 1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles |
| DRUG | gemcitabine | 1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2005-12-20
- Last updated
- 2020-08-31
- Results posted
- 2020-08-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00267020. Inclusion in this directory is not an endorsement.